Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Carolyn Presley MD, MHS

Carolyn J. Presley MD, MHS

Assistant Professor, Thoracic Oncology/Geriatric Oncology, The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital/Solove Research Institute, Columbus, OH

Carolyn J. Presley, MD MHS is an Assistant Professor in the Division of Medical Oncology/Department of Internal Medicine at The Ohio State University, Comprehensive Cancer Center and The James Cancer Hospital/Solove Research Institute. She earned her undergraduate degree from the University of Minnesota, Twin Cities and her medical degree from Dartmouth Medical School. She completed residency in Internal Medicine and combined fellowship in Geriatric Oncology and Hematology at Yale University. She completed a Masters in Health Sciences, also at Yale, within the Robert Wood Johnson Foundation Clinical Scholars Program sponsored by the VA Connecticut Healthcare System. She is an active member of the Ohio State University Comprehensive Cancer Program, The American Geriatrics Society, and the American Society of Clinical Oncology. She has been a long-time member of the international Cancer and Aging Research Group (CARG). Dr. Presley currently leads studies focused on maintaining functional independence among older adults with lung cancer. These studies incorporate geriatric assessment, embedded palliative care, and interventions to improve risk factors for treatment toxicity and functional decline.

Recent Contributions to PracticeUpdate:

  1. Pembrolizumab in Patients With NSCLC of Performance Status 2